iBio (IBIO) Q4 2026 earnings summary

Executive summary

• Transitioned to a clinical-stage company with the initiation of the Phase 1 trial for IBIO-600, targeting muscle preservation and improved body composition.

• Advanced IBIO-610 into IND-enabling studies, showing promising preclinical results for fat-selective weight loss and prevention of weight regain post-GLP-1 therapy.

• Expanded pipeline with IBIO-800 and in-licensed AstralBio's amylin receptor antibody program for obesity and metabolic diseases.

• Strengthened leadership with new Board and executive appointments.

Financial highlights

• Fiscal year 2026 revenue was $0.1 million, down from $0.4 million in 2025.

• R&D expenses rose to $19.6 million from $8.3 million year-over-year, mainly due to increased consulting and milestone payments.

• General and administrative expenses were stable at $10.6 million versus $10.7 million last year.

• Recorded a $5.0 million impairment on indefinite-lived intangible assets (IBIO-101).

• Net loss widened to $33.0 million from $18.4 million year-over-year.

• Cash, cash equivalents, and investments in debt securities totaled $88.0 million as of June 30, 2026.

Outlook and guidance

• Cash runway extended into fiscal year 2028 following successful financings.

• Plans to advance IBIO-600 into multiple ascending dose escalation and continue clinical development of pipeline assets.